We are pleased to inform about another success of our long-time Customer - Selvita S.A.
“Kraków/Berlin, 28 March 2017 – Selvita S.A., one of the largest biotechnological companies in Europe, announced today that it concluded a global license agreement with Berlin-Chemie Menarini, a company from the Italian Menarini Group, concerning the SEL24 project, which is a dual inhibitor of kinases PIM and FLT3, currently undergoing tests of I/II clinical phase in the refractory form of acute myeloid leukemia AML.
SEL24 compound is a dual inhibitor of kinases PIM and FLT3 developed by Selvita, playing a key role in the process of cancer creation, which is acute myeloid leukemia. SEL24 is a first-in-class drug using such a mechanism.
SEL24 compound was administered to the first patient in March 2017, and has currently been undergoing tests of I/II clinical phase, conducted in several clinical centers in the United States.”
[Text source and photo – www.selvita.com]
The concluded agreement has translated into a rapid increase in the company’s share prices, the capitalization of which comes close to PLN 1 billion.